众生药业: 关于公司股票交易异常波动的公告

Group 1 - The company's stock experienced an abnormal trading fluctuation, with a cumulative price increase exceeding 20% over two consecutive trading days on June 9 and June 10, 2025 [1] - The board of directors conducted a verification regarding the stock's abnormal fluctuation and confirmed that there are no undisclosed significant information or major matters under planning that could impact the stock [1][2] - The board also stated that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's listing rules, and previous disclosures do not require correction or supplementation [2] Group 2 - The company plans to change the use of part of the raised funds, reallocating approximately 43.26 million yuan and 4.93 million yuan from unused funds for the "anti-tumor drug R&D project" and "digital platform upgrade project" respectively, to support the new drug R&D project of its subsidiary [3] - This change in fundraising usage is aimed at more scientifically and effectively utilizing the raised funds in line with the company's overall strategic layout and operational development needs [3]